PAI1 is a Marker of Bad Prognosis in Rectal Cancer but Predicts a Better Response to Treatment with PIM Inhibitor AZD1208.

We found that patients in our cohort with higher PAI1 expression showed a decrease in disease-free survival (DFS) compared to that in patients with lower PAI1 expression, although it did not reach statistical significance ( Figure 1 G; p = 0.076).

also in 111,027 other papers

Among the found drug target genes, we observed highly significant positive correlations for some of the most representative drug target genes used in the treatment of rectal cancer ( Figure 4 B).

also in 132,142 other papers